<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646801</url>
  </required_header>
  <id_info>
    <org_study_id>NMB PP CLD 2158</org_study_id>
    <nct_id>NCT01646801</nct_id>
  </id_info>
  <brief_title>Study of NMB Drug Ejecting Balloon for Peripheral Arteries</brief_title>
  <official_title>The Use of NMB Drug Ejecting Balloon for Treatment of Patients With Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>N.M.B. Medical Applications Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>N.M.B. Medical Applications Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's
      drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral
      arterial disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss (LLL)</measure>
    <time_frame>6 months</time_frame>
    <description>Late Lumen Loss (LLL) defined as the difference between the minimal luminal diameter after the procedure and at 6 months, as evaluated by Quantitative Angiography (mm units will be used)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate</measure>
    <time_frame>6 months</time_frame>
    <description>Restenosis is defined as stenosis of at least 50% of the luminal diameter at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Malfunction</measure>
    <time_frame>intraprocedural, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>intraprocedural, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NMB's Paclitaxel Drug ejecting balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NMB Balloon Catheter</intervention_name>
    <description>patients treated by the NMB's Drug Ejecting Balloon</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years old or older

          -  Patient with lifestyle limiting claudication or rest pain (Rutherford- Becker scale 2,
             3 or 4).

          -  Patient with de novo lesion or restenotic lesion â‰¥70% in the iliac, femoral, popliteal
             or tibial artery.

          -  The target lesion can be successfully crossed with a guide wire and dilated.

          -  The target lesion is in a native artery of 2.5-10mm in diameter and less than 80 mm in
             length.

          -  Patient is willing to and able to sign a written informed consent and to comply with
             procedures (e.g., adherence to follow-up visits, including 6 months CT-angiography/MRA
             follow-up).

        Exclusion Criteria:

          -  Women who are pregnant or breast-feeding and women of childbearing potential who do
             not use adequate contraception.

          -  Previous participation in another study with any investigational drug or device within
             the past 30 days.

          -  The patient is currently enrolled in another investigational device or drug trial.

          -  Severe reaction to contrast agents that cannot be adequately premedicated prior to
             procedure.

          -  Stenosis with corresponding thrombosis treated within 7 days before enrollment.

          -  Patient with known contraindications for aspirin or other anticoagulant/antiplatelet
             therapy.

          -  Patient that has co-morbid illness that may result in life expectancy of less than 12
             months.

          -  History of haemorrhagic stroke or gastro-intestinal bleeding within 6 months.

          -  Patient with major surgery during the 30 days preceding the interventional procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eli Atar, MD</last_name>
    <phone>972-3-9376389</phone>
    <email>elia@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Rabin Medical Center, Hasharon Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 22, 2012</last_update_submitted>
  <last_update_submitted_qc>July 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

